Jump to main content
Jump to site search


Reversing the undesirable pH-profile of doxorubicin via activation of a di-substituted maleamic acid prodrug at tumor acidity

Author affiliations

Abstract

The acid-labile behavior of di-substituted maleamic acid (DMA) and its equilibrium with di-substituted maleimide (DMI) are exploited to build an ultra acid-sensitive, small molecule prodrug that can be activated by tumor extracellular pH (pHe) in the range of 6.5–6.9. Such a DMA prodrug reversed the unfavorable pH-profile of doxorubicin (Dox), which may improve its therapeutic window.

Graphical abstract: Reversing the undesirable pH-profile of doxorubicin via activation of a di-substituted maleamic acid prodrug at tumor acidity

Back to tab navigation

Supplementary files

Publication details

The article was received on 01 Sep 2017, accepted on 31 Oct 2017 and first published on 01 Nov 2017


Article type: Communication
DOI: 10.1039/C7CC06843C
Citation: Chem. Commun., 2017, Advance Article
  •   Request permissions

    Reversing the undesirable pH-profile of doxorubicin via activation of a di-substituted maleamic acid prodrug at tumor acidity

    A. Zhang, L. Yao and M. An, Chem. Commun., 2017, Advance Article , DOI: 10.1039/C7CC06843C

Search articles by author

Spotlight

Advertisements